Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Nucleus Medical GmbH currently manages 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to distinct examiners, ensuring that the company's prosecution is not overly dependent on any single official. The actions are also spread across a matching number of distinct art units, which indicates a wide technical distribution for the company's active intellectual property.
ASHLEE ELIZABETH WERTZ is the busiest examiner for the portfolio, overseeing 1 pending office action. Because the busiest examiner pending count is only one-third of the 3 total pending office actions, the company must manage multiple separate lines of communication with the patent office. This one to one ratio between actions, examiners, and art units suggests that each application is being treated as a unique technical and procedural challenge. Practitioners should be prepared to adapt their arguments to the specific standards of the various art units and the preferences of the different examiners to advance the medical portfolio effectively.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WERTZ, ASHLEE ELIZABETH | 1 | 52.7% | +35.6% |
| MERCIER, MELISSA S | 1 | 72.1% | +5.8% |
| LEE, SIN J | 1 | 68.8% | +25.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18568694 | NON-NANOPARTICULATE APPLICATION FORMS OF MACROLIDES | MERCIER, MELISSA S | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17839786 | NON-NANOPARTICULATE APPLICATION FORMS OF MACROLIDES | LEE, SIN J | 58d overdue |
| 18844505 | TRANSMUCOSAL THERAPEUTIC SYSTEM CONTAINING A MACROLIDE IMMUNOSUPPRESSANT | WERTZ, ASHLEE ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1615 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18844505 | TRANSMUCOSAL THERAPEUTIC SYSTEM CONTAINING A MACROLIDE IMMUNOSUPPRESSANT | WERTZ, ASHLEE ELIZABETH | 1612 | §103§112DP | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18568694 | NON-NANOPARTICULATE APPLICATION FORMS OF MACROLIDES | MERCIER, MELISSA S | 1615 | §102§103§112 | Final Rejection | 14d | Pending | Dec 08, 2023 |
| 17839786 | NON-NANOPARTICULATE APPLICATION FORMS OF MACROLIDES | LEE, SIN J | 1613 | §103 | Non-Final OA | 58d overdue | Pending | Jun 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNucleus Medical GmbH has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Ashlee Elizabeth Wertz has the most, with 1 of Nucleus Medical GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
